This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SNMMI 2024
AMA 2024
ASCO 2024
AUA 2024
APCCC 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2023
ASCO GU 2023
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Carcinoma
Press Releases
Penile, Urethral, Testicular, and Adrenal Cancers
ASCO GU 2023 Prostate Cancer
Viewing 21-40 of 95 articles
ASCO GU 2023: Impact of 68Ga-PSMA PET/CT in Patients with mCRPC Treated with Enzalutamide
ASCO GU 2023: Effect of Body Weight on Standardized Uptake Values on 18F-DCFPyL PSMA PET/CT in Patients with Prostate Cancer
ASCO GU 2023: Niraparib with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair Gene Alterations: Second Interim Analysis of MAGNITUDE
ASCO GU 2023: Clinical Implementation of 177Lu-PSMA-617 at a Major Academic Center: Initial Experiences
ASCO GU 2023: Developing a Novel Patient-Reported Outcome Measure for Patients with Prostate Cancer Receiving Radionuclide Therapy: The FACT-RNT
ASCO GU 2023: AlphaBet: A Phase I/II Trial Evaluating the Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in Patients with mCRPC
ASCO GU 2023: First-in-Class Oral Innate Immune Activator BXCL701 Combined with Pembrolizumab in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC) of Small Cell Neuroendocrine (SCNC) Phenotype: Phase 2a Final Results
ASCO GU 2023: Randomized, Double-Blinded Phase II Study of Ketoconazole, Hydrocortisone, and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC)
ASCO GU 2023: A Phase I/II Dose-Escalation Study of Fractionated 225Ac-J591 for Progressive mCRPC in Patients with Prior Treatment with 177Lu-PSMA
ASCO GU 2023: 68GaPSMA-11 PET/CT to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and PSMA Response
ASCO GU 2023: Dosing, Safety, and Pharmacokinetics of Combination Therapy with Darolutamide, ADT, and Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the ARASENS Study
ASCO GU 2023: Detection of True Positive M1 Lesions by 18F-rhPSMA-7.3 PET in Newly Diagnosed Prostate Cancer: Results from the Phase 3 Prospective LIGHTHOUSE Study
ASCO GU 2023: Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study
ASCO GU 2023: Results of a Multicenter, Randomized, Phase 3 Trial of Trimodality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Long- Versus Short-Term ADT for Localized High-Risk Prostate Cancer (TRIP/TRIGU0907)
ASCO GU 2023: Efficacy and Safety of Abiraterone Acetate plus Prednisone and ADT +/- Docetaxel in Older Patients (≥70 Years), with De Novo mCSPC, Compared to Younger Patients (70 Years): The PEACE-1 Trial
ASCO GU 2023: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis
ASCO GU 2023: Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories
ASCO GU 2023: 10-Year Efficacy and Co-Morbidity Outcomes of a Phase III Randomised Trial of Conventional vs. Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer (CHHiP; CRUK/06/016)
ASCO GU 2023: New Targets, New Concepts for Metastatic Castration-Resistant Prostate Cancer
ASCO GU 2023: How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free